Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...  Neurotech Pharmaceuticals, Inc., announced today the first ... 2 clinical trial of NT-503 Encapsulated Cell Therapy ... choroidal neovascularization secondary to age related macular degeneration ... growth factor (VEGF) receptor protein continuously produced by ... proof-of-concept study will evaluate NT-503 ECT as a ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 /PRNewswire/ ... today announced the intent of the National Institute of Allergy ... of Health (NIH) within the Department of Health and Human ... be held in the United States ... of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as a ...
(Date:9/2/2015)... ... 02, 2015 , ... The TS5-Q is designed for myriad ... to analysis of athletic performance. Producing high-resolution slow-motion video , the TS5-Q ... process with the naked eye. , Slow motion sequences are commonly seen ...
(Date:9/1/2015)... 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), ... of targeted antiviral therapies, announced today that it will ... Annual Global Investment Conference sponsored by H.C. Wainwright ... The St. Regis Hotel in New York, ... , Chief Executive Officer, will provide an overview of ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... first executive director of The Morgridge Institute for Research ... instrumental in shaping its direction and values. And the ... the new private, not-for-profit research institute is officially seeking ... position. The institute's core mission is to bring together ...
... Ramirez has little need for market research, especially when he ... user base is part of the creative class, and your ... can turn a soft voice into a baritone, end-users find ... of Screaming Bee, LLC , has paid attention to ...
... ., a privately-held biopharmaceutical company, has raised $3.3 million ... private investment firm based in Lake Forest, Ill. , ... trials of its treatment for the infections of large ... its core technology - therapies for the treatment of ...
Cached Biology Technology:Users help software company morph in new directions 2Users help software company morph in new directions 3Users help software company morph in new directions 4ConjuGon raises $3.3 million to fund clinical trials 2
(Date:8/12/2015)... NEW YORK , Aug. 12, 2015 /PRNewswire/ ... how hackers can attack Android phones to steal ... identifies the increasing availability of fingerprint scanners on ... of utmost concern. To secure biometrics on mobile ... platform to augment these convenient authentication systems with ...
(Date:8/10/2015)... 10, 2015 The latest 364 page ... analysis of the global border security market . ... $16.4bn in 2015. Now: Border security is hard ... of the business critical issue you need to know about ... ,s objective analysis of how this will impact your company ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... team of researchers from the United States, Korea, and France ... strains of E. coli bacteria, one used to ... research or practical applications. The findings will help guide future ... understanding of classical research that is the foundation of our ...
... research is suggesting new ways to aid recovery after ... recovery rate and show how to make stem cell ... presented at Neuroscience 2009, the annual meeting of the ... emerging news on brain science and health. In ...
... of tons of fruits and vegetables in the United States ... to the U.S. Department of Agriculture? A Georgia State ... produce and flowers fresh for longer periods of time. ,Microbiologist ... larger than the width of a human hair to ...
Cached Biology News:Genomes of 2 popular research strains of E. coli sequenced 2Genomes of 2 popular research strains of E. coli sequenced 3Researchers find ways to encourage spinal cord regeneration after injury 2GSU professor develops new method to help keep fruit, vegetables and flowers fresh 2